Gliclazide

Not to be confused with glipizide or glyburide.
Gliclazide
Clinical data
Trade namesDiamicron, Diaprel, Azukon, others[1]
AHFS/Drugs.comMicromedex Detailed Consumer Information
Pregnancy
category
  • AU: C
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life10.4 hours
Identifiers
  • N-(hexahydrocyclopenta[c]pyrrol-2(1H)-ylcarbamoyl)-4-methylbenzenesulfonamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.040.221 Edit this at Wikidata
Chemical and physical data
FormulaC15H21N3O3S
Molar mass323.41 g·mol−1
3D model (JSmol)
Melting point180 to 182 °C (356 to 360 °F)
  • O=S(=O)(c1ccc(cc1)C)NC(=O)NN3CC2CCCC2C3
  • InChI=1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19) checkY
  • Key:BOVGTQGAOIONJV-UHFFFAOYSA-N checkY
  (verify)

Gliclazide, sold under the brand name Diamicron among others, is a sulfonylurea type of anti-diabetic medication, used to treat type 2 diabetes.[7] It is used when dietary changes, exercise, and weight loss are not enough.[4] It is taken by mouth.[7]

Side effect may include low blood sugar, vomiting, abdominal pain, rash, and liver problems.[4][7] Use by those with significant kidney problems or liver problems or who are pregnant is not recommended.[7][4] Gliclazide is in the sulfonylurea family of medications.[7] It works mostly by increasing the release of insulin.[7]

Gliclazide was patented in 1966 and approved for medical use in 1972.[8] It is on the World Health Organization's List of Essential Medicines.[9] It is not available for sale in the United States.[10]

  1. ^ "Gliclazide - Drugs.com". www.drugs.com. Archived from the original on 27 December 2016. Retrieved 27 December 2016.
  2. ^ "Gliclazide GH MR, Gliclazide LAPL MR, Gliclazide Lupin MR (Lupin Australia Pty Limited)". Therapeutic Goods Administration (TGA). 5 December 2022. Archived from the original on 18 March 2023. Retrieved 7 April 2023.
  3. ^ "Product monograph brand safety updates". Health Canada. 7 July 2016. Archived from the original on 29 March 2024. Retrieved 3 April 2024.
  4. ^ a b c d "Gliclazide Accord-UK 30mg Prolonged-release Tablets - Summary of Product Characteristics (SmPC)". (emc). 12 February 2021. Archived from the original on 22 September 2022. Retrieved 30 December 2021.
  5. ^ "Diamicron 30 mg MR Tablets - Summary of Product Characteristics (SmPC)". (emc). 11 May 2020. Archived from the original on 23 December 2023. Retrieved 29 December 2021.
  6. ^ "Dacadis MR 30mg Modified Release Tablets - Summary of Product Characteristics (SmPC)". (emc). 15 July 2020. Archived from the original on 8 November 2023. Retrieved 29 December 2021.
  7. ^ a b c d e f British National Formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 474. ISBN 9780857111562.
  8. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 449. ISBN 9783527607495. Archived from the original on 27 December 2016.
  9. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  10. ^ "Gliclazide Advanced Patient Information - Drugs.com". www.drugs.com. Archived from the original on 27 December 2016. Retrieved 27 December 2016.